CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective upped by equities researchers at Truist Financial from $460.00 to $520.00 in a research report issued on Tuesday,Benzinga ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by Royal Bank of Canada from $402.00 to $407.00 in a research note issued to investors on Tuesday,Benzinga reports.

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

Shares of Biogen Inc. tumbled more than 5% on Wednesday morning, hitting their lowest levels since January 2013, as the ...

The U.S. agency that oversees Medicare is taking out questions on enrollment application forms that ask people about their ...

Co (market cap: $42.4 billion) reported robust Q4 2024 earnings, exceeding Wall Street forecasts with adjusted earnings per share (EPS) of $0.99, compared to the expected $0.82. Revenue also surpassed ...

What is ASX reporting season? Reporting or earnings season refers to the time of year when most publicly listed companies release their financial results to the market and announce the dividends ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

124 Years of the Australian Stock Market A breakdown of the Australian stock market’s historical returns since 1900. Presented in an easy-to-digest visual layout. Updated October 2024.